|
Session 39
Oral Abstracts
Cardiovascular Risk, Mortality and Tuberculosis Complicating HIV Infections
Wednesday, 10 am-12 noon
Room: Auditorium |
| 10:00 am 139 |
Elevated Levels of Interleukin-6 and D-dimer Are Associated with an Increased Risk of Death in Patients with HIV
Lewis Kuller and SMART Study Group
Univ of Pittsburgh, PA, US |
| 10:15 am 140 |
HIV Activates Markers of Cardiovascular Risk in a Randomized Treatment Interruption Trial: STACCATO
Alexandra Calmy*1, A Nguyen1, F Montecucco1, A Gayet-Ageron1, F Burger1, F Mach1, A Carr2, S Ubolyam3, B Hirschel1, J Ananworanich3,4, and for the Staccato study team
1Geneva Univ Hosp, Switzerland; 2St Vincent`s Hosp, Sydney, Australia; 3HIV Netherlands Australia Thailand Res Collaboration, Bangkok; and 4South East Asia Res Collaboration with Hawaii, Bangkok, Thailand |
| 10:30 am 141 |
Age- and Sex-specific Death Rates in ART-naïve Patients with CD4 Count above 350 cells/mm3 Compared with the General Population
Rebecca Lodwick*1, K Porter2, C Sabin1, B Ledergerber3, A Cozzi-Lepri1, P Khaykin4, A Mocroft1, L Jacobson5, S de Wit6, A Phillips1, and Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients
1Univ Coll London, UK; 2Med Res Council Clinical Trials Unit, London, UK; 3Univ Hosp Zurich, Switzerland; 4Johann Wolfgang Goethe Univ, Frankfurt, Germany; 5Johns Hopkins Univ, Baltimore, MD, US; and 6St Pierre Univ Hosp, Brussels, Belgium |
| 10:45 am 142 |
Immediate vs Deferred ART in the Setting of Acute AIDS-related Opportunistic Infection: Final Results of a Randomized Strategy Trial, ACTG A5164
Andrew Zolopa*1, J Andersen2, L Komarow2, A Sanchez3, C Suckow4, I Sanne5, E Hogg6, W Powderly7, and ACTG A5164 Study Team
1Stanford Univ, Palo Alto, CA, US; 2Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Southern California, Los Angeles, US; 4Frontier Sci & Tech Res Fndn, Buffalo, NY, US; 5Univ of the Witswatersrand, Johannesburg, South Africa; 6Social & Sci Systems, Silver Spring, MD, US; and 7Univ Coll Dublin, Ireland |
| 11:00 am 143 |
Exogenous Re-infection with Multidrug- and Extensively Drug-resistant TB among TB/HIV Co-infected Patients in Rural South Africa
J Andrews1, Neel Gandhi*2, P Moodley3, S Shah2, L Bohlken3, T Moll4, M Pillay3, G Friedland1, W Sturm3, and Tugela Ferry Care and Research Collaboration
1Yale Univ Sch of Med, New Haven, CT, US; 2Albert Einstein Coll of Med, Bronx, NY, US; 3Nelson R Mandela Sch of Med, Durban, South Africa; and 4Philanjalo and Church of Scotland Hosp, Tugela Ferry, South Africa |
| 11:15 am 144 |
HIV Infection and Drug-resistant TB in Ukraine: A Threatening Convergence of 2 Epidemics?
I Dubrovina1, K Miskinis2, S Lyepshina3, Y Yann4, H Hoffmann5, R Zaleskis6, P Nunn7, and Matteo Zignol*7
1WHO, Project Office, Donetsk, Ukraine; 2WHO, Country Office, Kiev, Ukraine; 3Donetsk State Med Univ, Ukraine; 4Donetsk TB Reference Lab, Ukraine; 5Inst of Microbio and Lab Med, Asklepios Fachkliniken München-Gauting, Germany; 6WHO, European Regional Office, Copenhagen, Denmark; and 7WHO Headquarters, Geneva, Switzerland |
| 11:30 am 145 |
The Influence of TB on Early Mortality in the Themba Lethu Clinical Cohort, Johannesburg, South Africa
Daniel Westreich*1, S Badal-Faesen2, B Malope2, D Rubel2, Z Akiy2, P MacPhail2, A Van Rie1, and I Sanne2
1Univ of North Carolina at Chapel Hill, Sch of Publ Hlth, US and 2Univ of the Witwatersrand, Johannesburg, South Africa |
| 11:45 am 146LB |
Effects of 18-Month Physiological GH Replacement in Relatively GH-deficient Patients with HIV Lipodystrophy
J Lo, S You, B Canavan, J Liebau, G Beltrani, P Koutkia, H Lee, and Steven Grinspoon*
Massachusetts Gen Hosp, Boston, US |
|
